TherapeuticsMD Inc (TXMD)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
$1.82+2.25%
Close 2026-11-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
QuarterlyIQ Insights · TXMD
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -26.2% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has been missing across recent quarters and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 8 industry peers
TXMD — earnings in line
Dated 2026-05-12
Results of Operations and Financial Condition. The information provided in
Why it matters: Cash from operations was $944,000 in Q1. Staying above zero would support the company’s ability to fund its costs from cash coming in.
Supportive ifThe next report shows more than $0 in cash from operating activities.
Worry ifThe next report shows cash from operating activities at or below $0.
Why it matters: The company is exploring a sale, merger, or other deal. A signed deal could change the value and future of its royalty business.
Supportive ifA company filing or release names a signed deal, buyer, or clear sale or merger terms.
Worry ifThe company reports no deal, ends the review, or says talks failed.
Why it matters: License revenue rose to $724,000 in Q1, mainly from the Mayne license. Another rise would show that licensed product sales are bringing in more money.
Watch forQ2 license revenue tops $724,000, with the company linking the rise to sales of licensed products.
Also watch forQ2 license revenue falls below $724,000. The company links the drop to lower sales of licensed products.
Why it matters: The company had $8.4 million in cash at March 31, 2026. A sharp drop could raise concern about its ability to keep funding costs.
Worry ifThe next balance sheet reports cash below $8.4 million and the company reports no signed strategic deal.
Less concerning ifCash is at or above $8.4 million, or a signed deal adds cash or cuts near-term costs.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$99 on $10,000 · ±1.0% | How much price usually moves either way. |
| Bad day | $547 loss on $10,000 · 5.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,574 loss on $10,000 · 35.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.